NCT03368729
Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Therapeutic Antibody, Misc Inhibitor

Key Eligibility Criteria:

Gender: Female
Age: 18 Years and older (Adult), Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with known active central nervous system (CNS) metastases; Patients with known germline BRCA 1/2 mutations
https://ClinicalTrials.gov/show/NCT03368729